Patents by Inventor Andrew B. Mahon

Andrew B. Mahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220378670
    Abstract: The present invention relates to gel compositions comprising a polyurethane elastomer. The polyurethane elastomer is formed from the reaction of a polyol, a polyisocyanate, and optionally a polyurethane reaction catalyst, optionally in the presence of a topically acceptable carrier fluid. In some embodiments, the gel composition comprises a personal active ingredient or a healthcare active ingredient, which may be incorporated into the gel composition via a pre-load method or a post-load method. Also provided herein are gel pastes and topical formulations comprising the polyurethane elastomers, and methods of making the same.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 1, 2022
    Inventors: Michael J. ISAACMAN, Steven ISAACMAN, Andrew B. MAHON
  • Publication number: 20220323439
    Abstract: The present disclosure provides a topical pharmaceutical formulation comprising uracil and a penetration enhancer, method of administration the same. Also provided is a method of treating or preventing dermatoses associated with the administration of a 5-fluorouracil or a precursor or prodrug thereof, such as capecitabine. the penetration enhancer is selected from the group consisting of dimethyl isosorbide, isopropyl myristate, isopropyl palmitate, octyldodecanol, oleic acid, oleyl alcohol, polyrides, pyrrolidone, thymol, tricaprylin, triolein, myristic acid, medium chain triglycerides, linoleic acid, lauric acid, glycofurol, glyceryl monooleate, ethyl oleate, dimethyl sulfoxide, dibutyl sebacate, and mixtures thereof.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 13, 2022
    Inventors: Steven ISAACMAN, Andrew B. MAHON
  • Patent number: 10918641
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 16, 2021
    Assignees: The University of North Carolina at Chapel Hill, Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Charles R. Esther, Jr., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon
  • Publication number: 20180353511
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Application
    Filed: April 3, 2018
    Publication date: December 13, 2018
    Inventors: Charles R. Esther, JR., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon